TNFRSF9 and neoplasm: Nonetheless, due to the dose-limiting toxicities of urelumab and moderate efficacy of utomilumab, subsequent strategies largely focused on combination therapies that targeted 4-1BB along with other tumor-driving factors with the goal of drawing a potent anti-tumor response at a lower 4-1BB antibody dose, minimizing its associated adverse effects.